Small bowel ulcer bleeding due to suspected clopidogrel use in a patient with clopidogrel resistance: A case report

Abstract

BACKGROUND

Clopidogrel is a platelet aggregation inhibitor used for the management of cardiovascular disease. While antiplatelet therapy decreases cardiovascular events after successful coronary drug-eluting stenting, it increases the risk of gastrointestinal (GI) bleeding. About 20% of the patients who take clopidogrel exhibit resistance to the drug.

CASE SUMMARY

We report the first case of a small bowel bleeding ulcer in an 86-year-old man with clopidogrel resistance. He had a history of taking clopidogrel due to unstable angina. There was no evidence of bleeding in the stomach, duodenum, or colon through upper and lower GI endoscopies. The abdominal computed tomography showed the extravasation of radiocontrast media at the ileum. Because of unstable vital signs, emergency surgery was performed. Multiple ulcers with inflammation were found in the ileum. The pathologic findings revealed simple inflammation. The VerifyNow P2Y12 test showed clopidogrel resistance. One year after changing to aspirin, capsule endoscopy was performed and the small bowel ulcers were improved.

CONCLUSION

Small bowel ulcers and bleeding due to clopidogrel are not very common, but the prevalence is expected to increase in older age patients with risk factors despite clopidogrel resistance.

Key Words: Clopidogrel; Resistance; Small bowel; Multiple ulcers; Hematochezia; Surgery; Case report

Core Tip: Small bowel injury and bleeding are typical side effects of non-steroidal anti-inflammatory drugs and antiplatelet agents like aspirin. However, there are rare previous reports of small bowel injury and bleeding due to clopidogrel and the mechanisms of ulcer formation in patients receiving clopidogrel therapy are unclear. Here, we report the first case of a small bowel bleeding ulcer in an 86-year-old man with clopidogrel resistance.

INTRODUCTION

The causes of small bowel bleeding vary according to age. Tumors, Meckel’s diverticulum, Dieulafoy’s lesion, and Crohn’s disease are the common causes in young patients (< 40 years), whereas vascular lesions like angiodysplasia and small bowel lesions caused by non-steroidal anti-inflammatory drugs (NSAIDs) and antiplatelet drugs are the major cause of small bowel gastrointestinal (GI) bleeding in elderly patients (> 65 years)[1]. Small bowel injury and bleeding are typical side effects of NSAIDs and antiplatelet agents like aspirin[2]. However, small bowel bleeding caused by clopidogrel is not common. About 20% of the patients exhibit clopidogrel resistance with increased platelet activation and the resistance to this drug is associated with the risk of stent thrombosis[3]. There are no previous reports of small bowel ulcer bleeding suspected to be due to clopidogrel in a patient with clopidogrel resistance.

CASE PRESENTATION

Chief complaints

An 86-year-old male was admitted to our hospital with hematochezia.

History of present illness

The pain started 3 d ago, which was continuous cramping pain aggravated by meal, and severity of pain had increased from numeric rating scale of 3 to 8. The patient denied fevers, diarrhea or jaundice. Upon visit to the emergency room his blood pressure and heart rate were normal, but body temperature was elevated to 38 ºC.

History of past illness

He had a history of taking clopidogrel due to unstable angina, and aspirin or analgesics were not taken. And he had never complained of GI symptoms prior to taking clopidogrel.

Personal and family history

He was a nonsmoker, and no notable family history was found.

Physical examination

Physical examinations showed pale conjunctiva and his abdomen was soft with mild lower abdominal tenderness. His initial blood pressure was 80/50 mmHg, pulse rate was 102 beats per minute, respiratory rate was 23 breaths per minute, and body temperature was 36.8 °C.

Laboratory examinations

The baseline laboratory results were as follows: Hemoglobin level, 8.0 g/dL; white blood cell count, 6000/μL; platelet count, 185000/μL; blood urea nitrogen, 25.6 mg/dL; and C-reactive protein, 1.7 mg/dL. The levels of other routine blood chemistry markers were within the reference limits.

Imaging examinations

The levels of other routine blood chemistry markers were within the reference limits. Upper and lower gastrointestinal endoscopy were performed and upper gastrointestinal bleeding was excluded. However, in the lower gastrointestinal endoscopic findings, small bowel bleeding was suspected as the cause of the hematochezia (Figure 1). The abdominal computed tomography showed the extravasation of radiocontrast media at the ileum (Figure 2).

Figure 1 Initial endoscopic findings. A: Lower gastrointestinal endoscopic findings show the possibility of small bowel bleeding; B: No evidence of bleeding was observed in the ascending colon and cecum.

Figure 2 Alternate prism cover test findings. A: Extravasation of contrast media (orange arrow) in the ileum cross-section view; B: Sagittal view.

FINAL DIAGNOSIS

Final diagnosis was small bowel ulcer bleeding due to clopidogrel resistance.

TREATMENT

Because of unstable vital signs, emergency surgery was performed. Multiple ulcers with inflammation were found in the ileum (Figure 3). The pathologic findings revealed simple inflammation (Figure 4). VeryfyNow P2Y12 testing was performed to check the clopidogrel response (365PRU), and the results showed clopidogrel resistance.

Figure 3 Excised specimen of the ileum, measuring 50 cm in length with multiple ulcerative lesions (orange arrow).

Figure 4 Histopathologic findings in the ileum. A: Ulcer with inflammatory ulcer debris (orange arrow) [hematoxylin and eosin (H&E) stain, × 40]; B: New vascular proliferation consistent with granulation tissue formation (arrow) (H&E stain, × 200).

OUTCOME AND FOLLOW-UP

The patient was prescribed aspirin instead of clopidogrel. There were no complaining symptoms. One year after discharge, capsule endoscopy was performed and the small bowel ulcers were improved (Figure 5).

Figure 5 Capsule endoscopic findings one year after surgery. The previous multiple ulcers were not observed.

DISCUSSION

This is the first report of a small bowel ulcer bleeding, which was suspected to be due to clopidogrel use in a patient with clopidogrel resistance. Clopidogrel, a second-generation oral thienopyridine is most commonly used as dual antiplatelet therapy with aspirin for the treatment of cardiovascular disease[4]. However, despite the use of clopidogrel, a considerable number of patients continue to have cardiovascular events. This phenomenon is called clopidogrel resistance and reflects the failure of the molecule to inhibit the target of its action.

With respect to clopidogrel resistance, accumulating data from numerous clinical studies underscore the importance of high on-treatment platelet reactivity (HPR) as a prognostic risk factor. There are several methods to evaluate the platelet response to clopidogrel. Ex vivo measurements of ADP-induced platelet aggregation by light transmittance aggregometry is the most commonly used gold standard method[5].

VerifyNow is a simple, rapid, point-of-care test with the advantages of small sample volume, the use of whole blood, and no pipetting. The test is used to assess the effect of clopidogrel resistance on the P2Y12 inhibition of platelet function[6].

When HPR was defined as 5 and 20 μmol/L adenosine diphosphate-induced maximal platelet aggregation of ≥ 46% and ≥ 59%, respectively, and P2Y12 reaction units of ≥ 235, HPR determined by light transmittance aggregometry and VeryfiNow P2Y12 were well-matched, and the risk stratification between the two methods showed strong agreement[7].

The small bowel is a rare site of GI bleeding and a common site of obscure GI bleeding. It became possible to examine the small intestine through as double balloon endoscopy and capsule endoscopy[8,9].According to previous studies, the incidence of small bowel ulcers and bleeding due to NSAIDs was about eight times higher than that of patients who did not take NSAIDs[10]. Low-dose aspirin has been reported to cause small bowel injury and 57.6% of the chronic users had mucosal breaks[11]. The crude risk of GI events in patients taking no antiplatelet therapy was 1.6%. The risk in aspirin users was 4.1%. The risk in clopidogrel users was 6.1%, and the risk in patients on both agents was 6.6%[12]. In a large cohort study, in over 75000 patients who took clopidogrel, the long-term risk of GI events like bleeding, ulcer, and erosion increased from 2% to 6%, comparing never-users with users[13]. However, this study had an observational design and included all GI bleeding. There is no mention of clopidogrel resisitance, so the difference in interstinal ulceration with or without clopidogrel resistance is unknown.

Some studies suggested that phospholipids and mitochondria in the intestinal cells are directly damaged by cyclooxygenase inhibition from NSAIDs. This result induces a decrease in energy synthesis and the generation of free radicals. Then, intercellular junctions are disrupted and intestinal permeability is increased[14]. Another report suggested that the intestinal mucosal barrier is damaged by intraluminal contents such as bile acid, food, bacteria, and enzymes as a result of inflammation that occurs when neutrophils are activated[15]. There are rare previous reports of small bowel injury and bleeding due to clopidogrel and the mechanisms of ulcer formation in patients receiving clopidogrel therapy are unclear.

However, it has been hypothesized that an impairment in ulcer healing by adenosine diphosphate (ADP) receptor antagonists may cause gastrointestinal injury[16]. Platelet aggregation may play an important role in ulcer healing through the release of platelet-derived growth factors that promote angiogenesis and ulcer healing. ADP receptor antagonists may impair gastric ulcer healing by suppressing the release of platelet-derived growth factors[17].

To the best of our knowledge, small bowel ulcer bleeding in patients with clopidogrel resistance has not been reported. Theoretically, clopidogrel cannot cause GI bleeding including small bowel injury in patients with clopidogrel resistance. In this case, there were no specific medications leading to GI bleeding and simple inflammation with no specific disease was found in the histologic examination. Clopidogrel resistance was confirmed by VeryfyNow P2Y12 testing. These results led to the diagnosis of small intestinal ulcers and bleeding associated by clopidogrel. After undergoing an operation and changing clopidogrel to aspirin, the patient's symptoms and blood tests improved, so it could be expected that intestinal bleeding no longer occurred in the patient. However, capsule endoscopy was performed to completely exclude small bowel ulceration, and it was confirmed that small bowel ulceration did not occur. This supports our opinion even though we do not know the exact mechanism of small bowel bleeding in this patient with clopidogrel resistance.

The mechanisms of clopidogrel resistance are not fully elucidated but there are several opinions on the mechanism for clopidogrel resistance. First opinion includes inappropriate dosing or underdosing of clopidogrel and drug–drug interactions between clopidogrel and other drugs. Second opinion may be hepatic conversion of the active metabolite by cytochrome CYP2C19. Third opinion could include variable intestinal absorption of the prodrug or clearance of the active metabolite. Otherwise, ABC1 activity, increased release of ADP and platelet receptor polymorphisms have been suggested[18]. In this case, these mechanisms might cause inappropriate concentration and action of active metabolite of clopidogrel and lead to ulceration and bleeding of small bowel.

CONCLUSION

In conclusion, we reported the first case of a small bowel ulcer bleeding, which was suspected to be due to clopidogrel use in a patient with clopidogrel resistance. Small bowel ulcers and bleeding due to clopidogrel are not very common, but the prevalence is expected to increase in older age patients with risk factors despite clopidogrel resistance.